1. Ito, A., Hirai, K., Inoue, M., Koga, H., Suzue, S., Irikura, T., Mitsuhashi, S.: In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrobial Agents and Chemotherapy 1980, 17: 103–108.
2. Hirai, K., Ito, A., Abe, U., Susue, S., Irikura, T., Inoue, M., Mitsuhashi, S.: Comparative activities of AM-715, pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections. Antimicrobial Agents and Chemotherapy 1981, 19: 188–189.
3. Gadebusch, H. H., Koupal, L. R., Celozzi, E., Shungu, D. L., Bland, J., Weissberger, B., Pelak, B., Fisch, E., Chung, S. K., Huber, J.: Norfloxacin (MK-0366, AM-715), a new orally-absorbed synthetic compound for the treatment of bacterial infections. In: Periti, P., Grassi, G. G. (ed.): Current Chemotherapy and Immunotherapy, Volume 1. American Society for Microbiology, Washington, D.C., 1982, p. 351–353.
4. Ozaki, T., Uchida, H., Irukura, T.: Studies on metabolism of AM-715 in humans by high-performance liquid chromatography. Chemotherapy (Tokyo) 1981, 29, Supplement 4: 128–135.
5. Boppana, V. K., Swanson, B. N.: Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-perfomrance liquid chromatography. Antimicrobial Agents and Chemotherapy 1982, 21: 808–810.